左卡尼汀对于冠状动脉介入治疗后对比剂肾病的影响
2016-04-01张海峰
张海峰
左卡尼汀对于冠状动脉介入治疗后对比剂肾病的影响
张海峰
摘要
关键词左卡尼汀;血管造影术;对比剂肾病
作者单位:730900 甘肃省,白银市第一人民医院 心内科
Effect of Levocarnitine on Contrast-induced Nephropathy in Coronary Artery Disease Patients After Percutaneous Coronary Intervention
ZHANG Hai-feng.
Department of Cardiology, The First People’s Hospital of Baiyin City, Baiyin (730900), Gansu, China
Abstract
Objective: To investigate the effect of levocarnitine on contrast-induced nephropathy (CIN) in coronary artery disease (CAD) patients after percutaneous coronary intervention (PCI).
Methods: A total of 138 CAD patients with PCI were studied.Upon basic hydration, the patients were divided into 2 groups: Levocarnitine group, the patients received intravenous infusion of levocarnitine 2g at 24h before PCI and levocarnitine 2g/day after PCI for 4 days and Non-levocarnitine group.n=69 in each group.Blood levels of urea nitrogen (BUN), creatinine (Scr), creatinine clearance rate (Ccr) and the occurrence rate of CIN were compared between 2 groups at 24h and 72h after PCI.All contrast agent used in the operation was Ultravist non ionic low permeability contrast solution and the dosage was recorded during operation.
Results: Compared with Non-levocarnitine group, Levocarnitine group had decreased blood levels of BUN and Scr at 24h and 72h after operation; increased post-operative Ccr, all P<0.05; the occurrence rate of CIN in Levocarnitine group was lower than Non-levocarnitine group (5.80% vs 15.94%), P<0.05.
Conclusion: Application of levocarnitine has certain preventive and protective effect for CIN occurrence in CAD patients after PCI.
Key words Levocarnitine; Angiography; Contrast-induced nephropathy
(Chinese Circulation Journal, 2016,31:116.)
随着放射介入诊断技术的深入开展,尤其是经皮冠状动脉介入治疗(PCI)的快速进步,对比剂肾病(CIN)的发生率也随之不断上升。CIN发病率在一般人群发病率2%,但在慢性肾功不全、 糖尿病等高危人群中发病率明显增加[1]。而且肾功能不全是心血管疾病的独立危险因素之一[2],2001年Waybill 等[3]的研究显示CIN已经成为住院患者急性肾功能衰竭的第三大致病因素。CIN目前尚无理想的预防和治疗手段,水化治疗是目前公认的有效预防CIN的最基本措施[4]。本研究探讨左卡尼汀对CIN干预的有效性和可行性,以期对防治CIN提供新的方法。
1 资料与方法
入选病例均选取自2013-09至2014-10在我院住院行PCI的患者138例,随机将其分为左卡尼汀组和非左卡尼汀组,每组69例,两组患者入院至少前1个月内均未使用左卡尼汀类药物。入组标准:拟诊为冠心病并具有PCI指征的患者,所有入选病例均于术前化验肌酐(Scr)提示正常或仅轻度异常(Scr<150 µmol/L)。排除标准:年龄>80岁;1个月内曾使用左卡尼汀类药物;2周内曾使用过对比剂;合并明显的心力衰竭;合并严重肝、肾功能不全;伴有发热及感染性疾病;既往有碘对比剂等药物过敏者;凝血功能障碍者。两组入选病例血管造影前一般情况比较差异均无统计学意义(P>0.05),具有可比性(表1)。
水化方式的选择:两组患者均于PCI术前3 h起以1 ml/(kg·h)的速度静脉滴注生理盐水至术后24 h,同时要求患者适量饮水。左……
